TrialEBioMedicine2019

Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development.

Tianshun Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.